Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

MM1: Emergency Use Authorization of Remdesivir for Patients With Confirmed or Suspected COVID-19

In this concise presentation, Dr. Vikramjit Mukherjee discusses the indications, dosing guidelines, and special considerations outlined in the FDA emergency use authorization of remdesivir for treatment of COVID-19.
Vikramjit Mukherjee, MD
Released: May 22, 2020

Information on this Educational Activity

Faculty

Vikramjit Mukherjee, MD

Assistant Professor of Medicine
Division of Pulmonary, Critical Care, & Sleep Medicine
New York University School of Medicine
Director, Medical Intensive Care Unit
Bellevue Hospital
New York, New York

Vikramjit Mukherjee, MD, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Related Content

From Elliott Bosco, PharmD, and Clinical Care Options (CCO), expert commentary on the risks and costs of RSV to older adults in the United States

person default Elliott Bosco, PharmD, PhD Released: August 11, 2021

Video from CCO: overview of respiratory syncytial virus illness and vaccine development in older adults from Drs. Spencer Durham, Stefan Gravenstein, and Barbara Resnick.

Spencer Durham Headshot Spencer H. Durham, PharmD, BCPS, BCIDP person default Stefan Gravenstein, MD, MPH person default Barbara Resnick, PhD, CRNP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: July 21, 2021 Expired: July 20, 2022

CCO slides: overview of RSV illness and vaccine development in older adults.

Spencer Durham Headshot Spencer H. Durham, PharmD, BCPS, BCIDP person default Stefan Gravenstein, MD, MPH person default Barbara Resnick, PhD, CRNP Released: June 25, 2021

Dr. Jens Lundgren discusses recently published and unpublished data on the use of immunomodulatory agents to treat COVID-19 from CCO

Jens D. Lundgren, MD, DMSc Released: October 16, 2020
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue